South Korean biopharma company Hanmi Pharmaceutical announced on Tuesday that it has entered into an exclusive distribution agreement with Mexican pharmaceutical company Laboratorios Sanfer for efpeglenatide, its GLP-1 obesity therapy, and the Dapalon Family, Hanmi's flagship diabetes treatment portfolio (Dapalon Tab. and Dapalon Duo SR Tab.).

Under the agreement, Hanmi will supply efpeglenatide and the Dapalon Family, while Laboratorios Sanfer will be responsible for regulatory approval, marketing, distribution, and sales within Mexico. The partnership is expected to gradually expand collaboration across efpeglenatide and other metabolic disease treatments, including additional product launches and joint marketing strategies over the mid- to long term.

Ricardo Amtmann, Sanfer CEO, said: "As a leading pharmaceutical company in Mexico and Latin America, our vision is to improve patients' lives through innovative, high-quality products. With healthcare costs accounting for 34.6% of household spending in Mexico, improving accessibility to innovative treatments is critical. Hanmi's efpeglenatide and diabetes treatment portfolio meet these needs. Through this partnership, we aim to contribute to addressing the rapidly growing challenges of obesity and diabetes in Mexico."